Medical/Pharmaceuticals
HanAll Biopharma Opens Applications for the 2023 Pharmaceutical Industry Fellowship Program
* Applications for physicians trained in Indonesia now open until April 15, 2023 12:00 AM * The Pharmaceutical Industry Fellowship Program provides physicians with the opportunity to experience the various steps of the drug development process ROCKVILLE, Md. and SEOUL, South Korea, March 15, ...
2023-03-15 19:00
2835
Jacobio Pharma to Present Data of Three Preclinical Studies at the 2023 AACR Annual Meeting
BEIJING and SHANGHAI and BOSTON, Mass., March 14, 2023 /PRNewswire/ -- Jacobin Pharma (1167.HK) today announced that the company will present the results of three preclinical studies of KRASmulti inhibitor JAB-23425, CD73-STING iADC JAB-X1800, and Aurora kinase A inhibitor JAB-2485 in form of the...
2023-03-15 10:45
3925
Ascentage Pharma to Present Latest Results from Three Preclinical Studies at 2023 American Association for Cancer Research Annual Meeting
SUZHOU, China and ROCKVILLE, Md., March 14, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the latest results from three preclinical s...
2023-03-15 07:59
3720
Mabwell Launched First in human Clinical Trial of Its Iron Homeostasis Regulating Macromolecular Drug 9MW3011
SHANGHAI, March 14, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with the layout of whole industry chain, launched first in human clinical trial of its iron homeostasis regulating macromolecular drug 9MW3011. The study (CTR20230046) is a phase 1, single cente...
2023-03-14 23:42
3189
Simcere Zaiming Announces Clinical Collaboration to Evaluate SIM0235, a TNFR2 Monoclonal Antibody, in Combination with KEYTRUDA® (pembrolizumab) in a Phase 1 Trial in Advanced Solid Tumors and Cutaneous T-cell Lymphoma
NANJING, China, March 14, 2023 /PRNewswire/ -- Simcere Pharmaceutical Group Limited (2096.HK) (Simcere), an innovative global biopharmaceutical company, announced today that Simcere Zaiming, an innovative oncology pharmaceutical company of Simcere has entered into a clinical collaboration agreeme...
2023-03-14 20:00
3598
Patient Enrollment Completed for Phase III Clinical Trial of Akeso's Cadonilimab in Treatment of Gastric Cancer
HONG KONG, March 14, 2023 /PRNewswire/ -- Akeso, Inc. (9926.HK) announced that patient enrollment has been completed for its pivotal Phase III clinical trial for cadonilimab (PD-1/CTLA-4 bi-specific antibody, AK104), the world's first approved and marketed dual-immune checkpoint bi-specific antib...
2023-03-14 17:01
2453
DeepCare debuts at IDS Cologne 2023
COLOGNE, Germany, March 14, 2023 /PRNewswire/ -- DeepCare, a leading AI solution provider for dental care, debuts its latest innovative products at the International Dental Show (IDS) inCologne, Germany, from March 14th to 18th, 2023. IDS is the world's largest and most influential dental exhibit...
2023-03-14 16:00
2856
Austco Augments Industry-leading Nurse Call and Healthcare Communications Solutions with 4D Imaging Radar Fall Detection by Vayyar
International partnership will see sensor installations in senior care
facilities in all of Austco's operating regions, includingAustralia, the UK,
Canada, and the US.
DALLAS and TEL AVIV, Israel, March 13, 2023 /PRNewswire/ -- Austco
2023-03-13 22:00
3425
Porton Advanced and Bennu Biotherapeutics Announced a Strategic Partnership to Accelerate Cell Therapy Development for Solid Tumors
SUZHOU, China, March 13, 2023 /PRNewswire/ -- On March 7th, 2023, Suzhou Porton Advanced Solutions Ltd. (Porton Advanced) and Bennu Biotherapeutics (Bennubio) announced a strategic partnership to advance cell and gene therapy R&D pipelines. The partnership aims to accelerate the development of T-...
2023-03-13 20:00
2974
Zhongchao Inc. Releases Survey Results for Bone Marrow Cancer Patient Services with More than 80% Patients Indicating Full Satisfaction
SHANGHAI, March 13, 2023 /PRNewswire/-- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a platform-based internet technology company offering services to patients with oncology and other major diseases, today announced the survey results of bone marrow patient services provided by ...
2023-03-13 20:00
2849
AnnJi Pharmaceutical Announced A Licensing Agreement With Avenue Therapeutics To Develop And Commercialize AJ201, A First-In-Class Clinical Asset For The Treatment Of Kennedy's Disease
TAIPEI, March 10, 2023 /PRNewswire/ -- AnnJi Pharmaceutical Co. (AnnJi) has entered into an exclusive license agreement with Avenue Therapeutics Inc. (Avenue, NASDAQ: ATXI) for the development and commercialization of AJ201 in the U.S.,Canada, European Union, Great Britain, and Israel for spinal ...
2023-03-10 19:00
2473
Success for Surglasses Technology! First AR Surgery Completed in the United States
TAICHUNG, Taiwan, March 10, 2023 /PRNewswire/ -- Surglasses/Caduceus S from Taiwan Main Orthopaedic Biotechnology Co., Ltd. Achieves Landmark Success with Caduceus S AR Spine Navigation System for First Augmented Reality Surgery in the US using 2D C-Arm Imaging. Surglasses has achieved a signifi...
2023-03-10 16:26
2870
Allorion Therapeutics, a next-generation precision medicine company focusing on oncology and autoimmune diseases, raises $50 million Series B financing
BOSTON, March 9, 2023 /PRNewswire/ -- Allorion Therapeutics ("Allorion"), a biotech company focusing on next-generation precision medicine for oncology and autoimmune diseases, announces the completion of a$50 million Series B financing round, co-led by INCE Capital and Qiming Venture Partners, w...
2023-03-10 09:00
3011
Hugel Nominates Suk-yong Cha as Non-Executive Director
* Hugel's 22nd General shareholders' meeting to take place on March 30th * Proposed appointment of Suk-yong Cha as new non-executive director as an agenda item SEOUL, South Korea, March 9, 2023 /PRNewswire/ -- Hugel, a global total medical aesthetic company, announced onMarch 9th that it wil...
2023-03-09 23:00
3292
GenFleet Therapeutics to Present Phase I Data for GFH312 at 2023 American Society for Clinical Pharmacology & Therapeutics Meeting
SHANGHAI, March 9, 2023 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced the results from phase I study of GFH312 (RIPK1 inhibitor) monotherapy will be presented as a poster at the 2023 ASC...
2023-03-09 19:00
2391
World-First, 45,000 patients study to develop AI-based "precision medicine" for migraine relief - collaboration between Healint and University of Geneva, Switzerland
PALO ALTO, Calif., March 9, 2023 /PRNewswire/ -- Healint, the developer and
owner of Migraine Buddy – the world's largest migraine tracking and research
platform used by more than 3 million people – is announcing a collaboration
with the University ofGeneva.
2023-03-09 16:55
2721
Estrella Biopharma Announces FDA Clearance of IND Application for Phase I/II Clinical Trial (Starlight-1) of EB103, a CD19-Targeted ARTEMIS® T Cell Therapy, to Patients with B-Cell Lymphomas
Initiation of Phase I/II Clinical Trial (Starlight-1) Expected to Occur in Second Half of 2023 EMERYVILLE, Calif. and NEW YORK, March 8, 2023 /PRNewswire/ -- Estrella Biopharma, Inc. ("Estrella"), a biopharmaceutical company whose mission is to harness the evolutionary power of the human immune ...
2023-03-09 05:15
2552
BIORCHESTRA Participating in Two Upcoming Therapeutic RNA-Focused Events
CAMBRIDGE, Mass. and DAEJEON, South Korea, March 8, 2023 /PRNewswire/ --
BIORCHESTRA
2023-03-08 22:47
2716
Hovione receives the 2023 CDMO Leadership Award in all six categories and is Champion in Compatibility and Expertise
LISBON, Portugal, March 8, 2023 /PRNewswire/ -- Hovione, the leader in spray
drying and particle engineering, won the2023 CDMO Leadership Award
2023-03-08 22:00
2779
MSCI ESG Updated I-Mab to "A" Rating
GAITHERSBURG, MD. and SHANGHAI, March 7, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that I-Mab has been granted "A" rating by MSCI (Morgan ...
2023-03-07 21:02
2718
Week's Top Stories
Most Reposted
DayOne Files Registration Statement for Proposed Initial Public Offering
[Picked up by 279 media titles]
2026-10-06 05:28SMU School of Accountancy launches Applied AI Track for next generation of accounting and finance professionals
[Picked up by 279 media titles]
2026-10-07 11:50Zenika CTO Adrien Nortain Moves Base to Singapore to Strengthen Technical Leadership in Asia
[Picked up by 271 media titles]
2026-10-01 10:00
Vestas Powers Up Vietnam's Clean Energy Ambitions with Two New Projects Under PDP8 Totaling 16 Wind Turbines
[Picked up by 263 media titles]
2026-10-02 16:27
Southeast Asia's China travel map is widening, Traveloka platform data shows
[Picked up by 262 media titles]
2026-10-05 11:51Most Read
MixVio AI Launches Unified Creative Workspace Across 26 AI Generation Routes
2026-10-02 00:30
24115